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Abstract: Postmenopausal osteoporosis increases susceptibility to low-trauma fractures due to 
reduced bone volume and microarchitectural deterioration. Daily nitrogen-containing bisphos-
phonates have shown antifracture efﬁ  cacy in many studies and are the most commonly prescribed 
treatment for women with postmenopausal osteoporosis. However, optimal efﬁ  cacy is often not 
achieved due to poor patient adherence to medication. Current dosing schedules are often incon-
venient or impractical for patients. Poor adherence increases risk of fracture, which itself increases 
morbidity, healthcare costs and, potentially, mortality. Although weekly rather than daily dosing 
of bisphosphonates has improved adherence, signiﬁ  cant problems remain. Efforts to reduce dosing 
frequency as a possible means for further improving adherence (compliance and persistence), and 
therefore treatment outcomes, are ongoing. Risedronate, a third-generation bisphosphonate, has 
been shown in multiple clinical trials to reduce fracture risk and improve bone mineral density 
in postmenopausal women with osteoporosis. Risedronate has a speciﬁ  c structure and set of 
characteristics that enable less frequent dosing. This paper reviews the structure of risedronate, 
and how this translates into high antiresorptive potency, favorable bone binding, persistence in 
bone, and good tolerability that permits less frequent dosing. The paper also reviews the clinical 
evidence for risedronate, demonstrating the viability of less frequent dosing, with its potential 
beneﬁ  ts for patient convenience and adherence to therapy. Two equivalence or non-inferiority 
bridging studies have demonstrated the option of novel risedronate dosing regimens. These 
studies are reviewed to demonstrate the efﬁ  cacy and safety of two different monthly regimens 
of risedronate in the treatment of postmenopausal osteoporosis: 75 mg on 2 consecutive days a 
month and 150 mg once a month. Data for oral risedronate 150 mg once a month are limited to 
1 year´s treatment duration. In previous clinical trials, patients receiving risedronate 5 mg daily 
have been followed for up to 7 years, with no evidence of loss of effectiveness. Risedronate 
150 mg once a month has a comparable efﬁ  cacy and safety to daily doses in the treatment of 
postmenopausal osteoporosis. These additional treatment options with risedronate provide easier 
dosing alternatives for patients.
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Introduction
Osteoporosis has been deﬁ  ned as a systemic disease characterized by low bone 
mass and disruption of bone architecture resulting in reduced bone strength and an 
increased relative risk of fracture. The prevalence of osteoporosis is estimated at over 
200 million people worldwide (Reginster and Burlet 2006). In the US and Europe, 
about 30% of all postmenopausal women are affected by osteoporosis (Reginster 
and Burlet 2006). As the population ages worldwide, the number of people with 
osteoporosis is expected to rise correspondingly. Current annual rates of osteoporotic 
fractures are estimated at around 1.5 million in the US and 3.8 million in Europe 
(Reginster and Burlet 2006). In 1990, the incidence of new hip fractures worldwide Clinical Interventions in Aging 2008:3(2) 228
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was 1.7 million, but this ﬁ  gure is estimated to increase to 
2.6 million by 2025 (Reginster and Burlet 2006). Direct 
expenditure related to osteoporotic fractures was US$17 
billion in the US in 2001; in the European Union costs were 
US$32 billion in 2000 and are expected to double by 2050 
(Reginster and Burlet 2006).
Adherence to treatment 
of osteoporosis
Treatment to decrease the risk of osteoporotic fractures 
may include bisphosphonates, raloxifene, teriparatide, 
estrogen, calcitonin, and strontium ranelate. Despite the 
proven efﬁ  cacy of bisphosphonates in reducing both ver-
tebral and non-vertebral fractures, and increasing bone 
mineral density (BMD), not all patients gain maximum 
beneﬁ  t from these therapies. A major reason cited for 
suboptimal efﬁ  cacy of oral bisphosphonates is poor long-
term adherence to medication therapies, a common feature 
of chronic disease (WHO 2003). Poor adherence can have 
serious consequences. Studies have shown that patients 
who do not adhere to their dosing schedule have insufﬁ  -
ciently decreased bone resorption (Eastell et al 2003), lower 
treatment-related increases in BMD (Finigan et al 2001; 
Yood et al 2003; Sebalt et al 2004), and, most importantly, 
a signiﬁ  cantly increased risk of fracture (Caro et al 2004; 
McCombs et al 2004; Sebalt et al 2004).
Fractures resulting from poor adherence increase direct 
and indirect medical costs, and mortality (Chrischilles et al 
1991; Caro et al 2004; McCombs et al 2004). Both patient 
and medication factors are involved in this major problem, 
one being the complexity of the dosing regimen (Cramer 
et al 2007; Lekkerkerker et al 2007) or a complex dosing 
schedule of therapy (Mersfelder et al 1999; Lombas et al 
2001; Segal et al 2003).
Due to poor adherence to anti-osteoporotic treatments, 
maximizing compliance should be a primary focus of 
clinical management (NAMS 2006). Newer formulations 
of bisphosphonates have been developed. Dosing frequency 
inﬂ  uences compliance. Currently alendronate is available 
as a daily or weekly therapy and ibandronate is available 
as a monthly therapy. Risedronate in a daily, weekly, or a 
twice-monthly dosing regimen (75 mg on 2 consecutive 
days each month) was recently approved by the US Food 
and Drug Administration (FDA) (Brown et al 2002; Emkey 
2004; Delmas et al 2004, 2008; Miller et al 2005).
Patients prefer these new dosing formulations (Simon 
et al 2002; Baroutsou et al 2004; Kendler et al 2004) and 
consequently weekly dosing is associated with better persis-
tence (Cramer et al 2004; Ettinger et al 2004) and compliance 
(Cramer et al 2004; Ettinger et al 2004; Recker et al 2004) 
than daily dosing. Proven treatment efﬁ  cacy, however, is 
another important factor that affects patient preference (Gold 
et al 2006; Keen et al 2006; Weiss et al 2006). However, 
adherence rates with weekly regimens are still inadequate. 
Only 37%–58% of patients who received weekly bisphospho-
nate therapy remained persistent at 1 year, and just 46%–69% 
complied correctly (Cramer et al 2004; Ettinger et al 2004; 
Recker et al 2004). These data suggest a need for simpler 
and less frequent dosing.
A monthly therapy with vertebral, non-vertebral, and hip 
fracture reduction efﬁ  cacy would give physicians another 
treatment option. At the time of this study ibandronate 
150 mg is the only bisphosphonate approved for once-monthly 
administration. The treatment with monthly oral ibandronate 
produced signiﬁ  cant and progressive increases in lumbar 
spine (LS) BMD of 4.9% after 1 year in the MOBILE study. 
Furthermore 150 mg monthly regimen produced similar and 
signiﬁ  cant increases in hip BMD (total hip, femoral neck, 
and trochanter). Therefore, in women with postmenopausal 
osteoporosis, monthly ibandronate is at least as effective for 
BMD endpoints as daily ibandronate (Miller et al 2005). In a 
previous study daily ibandronate demonstrated a signiﬁ  cant 
reduction of risk of new morphometric vertebral fractures by 
50% (p = 0.0006) versus placebo and a statistically signiﬁ  cant 
relative risk reduction in clinical vertebral fractures of 48% 
was observed, but the incidence of non-vertebral fractures was 
not signiﬁ  cantly reduced. However, ﬁ  ndings from a posthoc 
analysis showed that the daily regimen reduces the risk of non-
vertebral fractures (69%; p = 0.012) in a higher-risk subgroup 
(femoral neck BMD T score 3.0 ) (Chesnut et al 2004).
Figure 1 Mean percentage change from baseline in lumbar spine mineral density. 
There were no statistically signiﬁ  cant differences between treatments groups at any 
time point.   After Delmas et al (2008).Clinical Interventions in Aging 2008:3(2) 229
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FDA and European Medicines Agency (EMEA) 
guidelines have determined that alternative dosage forms 
can be approved based upon BMD.
Characteristics of risedronate
Risedronate is a pyridinil bisphosphonate that has been 
shown in prospective fracture studies to reduce vertebral and 
non-vertebral fracture risk (Harris et al 1999; Reginster et al 
2000; McLung et al 2001). Several studies have shown that 
in patients with postmenopausal osteoporosis, risedronate 
increases BMD by 5.4%–5.9% in the LS and by 1.6%–3.1% in 
the femoral neck, and reduces vertebral fractures by 41%–49% 
and hip fractures by 40% (Harris et al 1999; Reginster et al 
2000; McClung et al 2001; Cranney et al 2002).
For an anti-osteoporotic drug to be administered at extended 
drug-free intervals and provide persistence of effect, it needs 
to possess certain properties. These properties include high 
antiresorptive potency, favorable bone binding characteristics, 
distribution, concentration, and persistence in bone tissue, and 
good tolerability. Clinical pharmacology and pharmacokinetic 
studies, and preclinical animal studies have shown risedronate 
to possess these characteristics. So, like other bisphosphonates, 
risedronate remains active on the surface of bone for long 
periods after dosing, providing the opportunity to develop 
a range of dosing schedules. Although the original dosing 
regimen for postmenopausal osteoporosis was an oral dose of 
5 mg risedronate daily, it was later demonstrated that 35 mg 
once a week provided similar efﬁ  cacy and safety to the daily 
regimen (Brown et al 2002). Risedronate 75 mg each day for 2 
consecutive days a month (2CDM) has also been shown to be 
effective, and was recently approved by the FDA for the treat-
ment and prevention of postmenopausal osteoporosis (Actonel 
label 2007; McCLung et al 2007; Delmas et al 2008).
Efﬁ  cacy and safety of monthly 
dosing of 75 mg risedronate on 
two consecutive days a month
This dosing regimen is one of the steps taken towards a 
once-a-month dosing regimen of 150 mg risedronate. To 
determine if risedronate 75 mg 2CDM regimen is non-
inferior to risedronate 5 mg daily, 1 year of treatment 
with risedronate 5 mg daily (n = 613) was compared 
with risedronate 2CDM in a international, phase III, 
randomized, double-blind, parallel-group multicenter study 
in postmenopausal women with osteoporosis (n = 616) 
(Delmas et al 2007).
The primary efﬁ  cacy endpoint was the percentage change 
from baseline in LS BMD at month 12.
Secondary efﬁ  cacy measures included mean percentage 
change from baseline in LS and hip BMD, as well as bone 
turnover markers (BTMs). In addition, the incidence of new 
vertebral fractures was determined, based on comparison of 
X-ray measurements from baseline to month 12.
Non-inferiority in increasing LS BMD was demonstrated 
with 75 mg 2CDM of risedronate, which represents the 
same cumulative monthly dose of risedronate (150 mg) as the 
5 mg daily dosing regimen (treatment difference 0.21: 95% CI 
0.19–0.62). Secondary efﬁ  cacy analyses similarly showed no 
clinically relevant differences between the 75 mg 2CDM and 
the 5 mg daily regimens of risedronate: the mean increases 
from baseline in LS BMD at 1 year were 3.4% (3.1, 3.7; 95% 
CI) vs 3.6% (3.3, 3.9; 95% CI), respectively. The results were 
also similar for mean percentage change from baseline in total 
hip, trochanter, and femoral neck BMD, and BTMs were 
signiﬁ  cant and similar for both treatments groups.
Although the study did not aim to measure fractures, 
the incidences of vertebral and non-vertebral fractures 
were similar in the two treatment groups and, for example, 
new vertebral fractures occurred after 1 year in only 1% 
of subjects treated with either risedronate dosing regimen. 
Treatment efﬁ  cacy in this study was similar to that in earlier 
reports with daily or weekly risedronate for both changes in 
BMD (Reginster et al 2000; Brown et al 2002; Harris 2004) 
and BTMs (Brown et al 2002; Harris et al 2004).
Safety and tolerability were good for both risedronate dos-
ing regimens, with comparable overall treatment-emergent 
adverse effects (TEAEs), TEAEs leading to withdrawal, 
gastrointestinal (GI) tolerability, fractures, and clinical labo-
ratory data. The most commom TEAEs were arthralgia and 
back pain in both treatment groups. The incidence of TEAEs 
potentially associated with acute phase reactions was low in 
both dosing groups and TEAEs were experienced in a higher 
number of subjects in the group treated with risedronate 
75 mg 2CDM (4 subjects) compared with the group taking 
5 mg risedronate daily (0 subjects). Only 9% of subjects in 
either treatment group discontinued treatment prematurely 
due to an AE, most commonly GI-related.
In conclusion, risedronate 75 mg 2CDM was non-inferior 
and was as well tolerated as 5 mg daily in postmenopausal 
women with osteoporosis.
Efﬁ  cacy and safety of risedronate 
150 mg once a month
A recent study has demonstrated comparable efﬁ  cacy and 
safety of risedronate 150 mg once-a-month dosing regimen 
to daily dosing for postmenopausal osteoporosis.Clinical Interventions in Aging 2008:3(2) 230
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Two years of treatment with risedronate 5 mg daily 
(n = 538) was compared with once-a-month risedronate 
(n = 556) in a international, phase III, randomized, double-
blind, parallel-group multicenter study in postmenopausal 
women with osteoporosis. The results for the ﬁ  rst year of the 
study have been published, which is continuing for a second 
year (Delmas et al 2008).
The primary endpoint analysis was a test of non-inferiority 
comparing the least mean percentage change from base-
line in LS BMD in the 150 mg once-a-month and 5 mg 
daily groups after 12 months. The month 12 measurement 
or the last postbaseline obtained prior to month 12 was 
used (last observation carried forward, also referred to 
as endpoint). This mean percentage change in LS BMD 
was 3.4% (95% CI 3.03%–3.82%) in the daily group and 
3.5% (95% CI 3.15%–3.93%) in the once-a-month group 
(Fig. 1) The difference between groups was –0.1% (95% 
CI –0.51%–0.27%). These results indicated that both 
groups experienced signiﬁ  cant improvement from base-
line in LS BMD and that the once-a-month regimen was 
non-inferior to the daily regimen based on prospectively 
deﬁ  ned criteria. There was no statistically signiﬁ  cant dif-
ference between the treatment groups in mean percentage 
change in LS BMD at any time (ie, month 6, month 12, 
or endpoint).
Signiﬁ  cant increases from baseline in BMD of sites in the 
proximal femur (total proximal femur, femoral neck, femoral 
trochanter) were observed al 6 months and 12 months in both 
treatment groups. As was the case for LS BMD, there was no 
statistical difference between treatment groups at any time 
point at any hip site.
There was no difference between treatment groups in the 
occurrence of new incident vertebral fracture as determined 
by morphometric measurement during the ﬁ  rst 12 months 
of treatment.
Significant decreases from baseline in BTMs were 
observed at 3, 6, and 12 months in both treatment groups 
and there was no statistically signiﬁ  cant difference between 
treatment groups at endpoint for any of the BTMs.
Both regimens were well tolerated; 9.5% of patients in the 
daily group withdrew from treatment as a result of an adverse 
event and 8.6% in the once-a-month group. Adverse events 
of special interest for bisphosphonates (clinical vertebral and 
non-vertebral fractures, upper GI, and musculoskeletal) were 
reported by similar proportions of patients in both treatments 
groups. Incidence of adverse events, adverse events leading 
to withdrawal, and upper GI adverse events was similar in 
both treatment groups.
Most events associated with possible acute phase reactions 
were determined by the investigator to be mild or moderate 
in severity; only 1 patient, in the once-a-month group, 
experienced a severe event. The incidence of symptoms 
potentially associated with an acute phase reaction, although 
low in both groups, was slightly higher in the monthly group 
(1.4%) than in the daily group (0.2%) (Table 1).
Atrial ﬁ  brillation was reported by 3 patients (0.5%) 
in the 5 mg daily group and 4 patients (0.6%) in the 
150 mg once-a-month group. There were no reported cases 
of osteonecrosis of the jaw.
In conclusion, risedronate 150 mg once a month is similar 
in efﬁ  cacy and safety to daily dosing and may provide an alter-
native for patients who prefer once-a-month oral dosing.
Conclusion
There is growing evidence to show that complex dosing regi-
mens contribute towards suboptimal adherence to bisphospho-
nates in women with postmenopausal osteoporosis. Several 
medications have been shown to decrease fracture rates in 
clinical trials. However, in real life settings, long-term persis-
tence and compliance to anti-osteoporosis medication is poor, 
hence decreasing the clinical beneﬁ  ts for patients. Dosing 
frequency inﬂ  uences compliance; although patients using 
weekly biphosphonate medication follow their prescribed 
dosing regimens better than those using daily therapy, overall 
compliance and persistence rates are suboptimal. Currently 
risedronate and alendronate are available as a weekly therapy 
and ibandronate is available as a monthly therapy.
Risedronate is an oral, nitrogen-containing 
bisphosphonate that possesses properties that provide easier 
dosing alternatives for patients, such as strong afﬁ  nity 
for bone, potent antiresorptive action, high concentration 
and persistence in bone tissue, and excellent tolerability. 
The results of recent clinical trials conﬁ  rm the viability 
of less frequent dosing with risedronate, and show these 
regimens to be well tolerated and effective in the treatment 
of postmenopausal osteoporosis. The study with risedronate 
75 mg 2CDM was one of the steps taken towards a once-
a-month dosing of 150 mg risedronate. The 75 mg 2CDM 
regimen has already been approved by the FDA for the 
treatment and prevention of postmenopausal osteoporosis.
Risedronate 150 mg once a month is comparable in 
safety and efficacy to daily dosing in the treatment of 
postmenopausal osteoporosis. Risedronate 150 mg once a 
month produces clinical effects similar to those seen with 
5 mg daily, including mean percentage change in BMD at 
the lumbar spine and the hip, bone turnover markers, and Clinical Interventions in Aging 2008:3(2) 231
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morphometric vertebral fractures. These ranges of risedro-
nate dosing options, from daily to weekly to monthly, have 
the potential to improve patient adherence to therapy, and 
thereby optimize therapeutic outcomes.
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